-2.73%
5.01%
10.56%
43.55%
44.72%
68.72%
-44.11%
AI Spotlight on XERS
Company Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology.The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect.
The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Market Data
| Last Price | 3.56 |
| Change Percentage | -2.73% |
| Open | 3.68 |
| Previous Close | 3.66 |
| Market Cap ( Millions) | 531 |
| Volume | 1873363 |
| Year High | 3.87 |
| Year Low | 1.69 |
| M A 50 | 3.35 |
| M A 200 | 2.7 |
Financial Ratios
| FCF Yield | -6.30% |
| Dividend Yield | 0.00% |
| ROE | 397.13% |
| Debt / Equity | -956.70% |
| Net Debt / EBIDTA | -917.94% |
| Price To Book | -18.73 |
| Price Earnings Ratio | -8.4 |
| Price To FCF | -15.87 |
| Price To sales | 2.83 |
| EV / EBITDA | -32.19 |
News
- Jan -21 - The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness
- Jan -10 - Xeris Expects to Exceed Full-Year 2024 Financial Guidance
- Nov -08 - Xeris Biopharma Holdings, Inc. (XERS) Q3 2024 Earnings Call Transcript
- Nov -08 - Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- Nov -08 - Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates
- Nov -08 - Xeris Biopharma Reports Third Quarter 2024 Financial Results
- Oct -25 - Xeris Biopharma Holdings: Promising Pipeline And Strategic Partnerships Make It Attractive
- Oct -11 - Undercovered Dozen: KinderCare Learning, Xeris Biopharma, Generac, Philips +
- Oct -09 - Xeris Biopharma: Time For A Reassessment
- Aug -30 - 3 Penny Stocks to Buy With $500
- Aug -08 - Xeris Biopharma Holdings, Inc. (XERS) Q2 2024 Earnings Call Transcript
- Aug -08 - Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
- Aug -01 - Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know
- Jul -24 - Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?
- Jul -08 - Xeris Biopharma unveils CEO succession plan, John Shannon to lead company
- May -09 - Xeris Biopharma sees 1Q revenue jump on strength of product sales
- May -09 - Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates
- May -06 - Xeris Biopharma and Beta Bionics join forces to develop dual-hormone pump for diabetes
- May -06 - Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
- Mar -30 - Xeris Biopharma: Checking-In On One Of My 'Top Ideas'
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Gvoke, Keveyis and Recorlev
Expected Growth : 10.5 %
What the company do ?
Gvoke is a ready-to-use, room-temperature stable glucagon injection for severe hypoglycemia, Keveyis is a treatment for periodic paralysis, and Recorlev is a cortisol synthesis inhibitor for Cushing's syndrome.
Why we expect these perspectives ?
Growing demand for convenient and effective treatments for severe hypoglycemia, periodic paralysis, and Cushing's syndrome, driven by increasing prevalence of these conditions, advancements in biotechnology, and Xeris Biopharma's innovative products, including Gvoke, Keveyis, and Recorlev, which offer improved patient outcomes and convenience.
Segment n°2 -> Royalty, Contract and Other
Expected Growth : 12.4 %
What the company do ?
Xeris Biopharma Holdings, Inc. has Royalty fees from licensed products, Contract revenue from collaborations, and Other income from miscellaneous sources.
Why we expect these perspectives ?
Xeris Biopharma's royalty fees from licensed products, contract revenue from collaborations, and other income from miscellaneous sources are expected to drive growth. Increasing demand for innovative biopharmaceuticals, strategic partnerships, and expanding product portfolios are key growth drivers.
Xeris Biopharma Holdings, Inc. Products
| Product Range | What is it ? |
|---|---|
| Gvoke | Gvoke is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes. |
| Ogluo | Ogluo is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes. |
| Gvoke HypoPen | Gvoke HypoPen is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes. |
| XeriSol | XeriSol is a ready-to-use, room-temperature stable glucagon injection for the treatment of severe hypoglycemia in people with diabetes. |
Xeris Biopharma Holdings, Inc.'s Porter Forces
Threat Of Substitutes
Xeris Biopharma Holdings, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on developing innovative and differentiated products.
Bargaining Power Of Customers
Xeris Biopharma Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are often critical to customers' operations, making it difficult for them to negotiate prices.
Bargaining Power Of Suppliers
Xeris Biopharma Holdings, Inc. relies on a few key suppliers for raw materials and services. While the company has some bargaining power due to its size, suppliers may still have some leverage in negotiations.
Threat Of New Entrants
The biopharmaceutical industry is highly competitive, and new entrants can easily disrupt the market. Xeris Biopharma Holdings, Inc. must continually innovate and differentiate its products to stay ahead of new competitors.
Intensity Of Rivalry
The biopharmaceutical industry is highly competitive, with many established players and new entrants vying for market share. Xeris Biopharma Holdings, Inc. must be highly competitive in terms of pricing, product offerings, and innovation to maintain its market position.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 103.61% |
| Debt Cost | 9.93% |
| Equity Weight | -3.61% |
| Equity Cost | 9.93% |
| WACC | 9.93% |
| Leverage | -2866.81% |
Xeris Biopharma Holdings, Inc. : Quality Control
Xeris Biopharma Holdings, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| OABI | OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies … |
| SYRS | Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates … |
| MNKD | MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled … |
| KYMR | Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It … |
| ATNM | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
MannKind
A-Score
1-Year Total Return ->
🥉
Kymera Therapeutics
A-Score
1-Year Total Return ->
4
OmniAb
A-Score
1-Year Total Return ->
5
Syros Pharmaceuticals
A-Score
1-Year Total Return ->
6
